Adial Pharmaceuticals, Inc. (ADIL)
Stock Price:
$1.32 USD
-0.06 (-4.35%)
Updated Jul 14, 2020 1:22 PM EDT - Market open
Key Info
| Market Cap |
17.75M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-8.19M |
| Shares Out |
13.45M |
| EPS (ttm) |
-0.79 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 14, 2020 |
| Last Price |
$1.32 |
| Previous Close |
$1.38 |
| Change ($) |
-0.06 |
| Change (%) |
-4.35% |
| Day's Open |
1.37 |
| Day's Range |
1.31 - 1.38 |
| Day's Volume |
132,911 |
| 52-Week Range |
1.00 - 3.17 |
More Stats
| Market Cap |
17.75M |
| Enterprise Value |
12.80M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
13.45M |
| Float |
8.41M |
| EPS (basic) |
-0.79 |
| EPS (diluted) |
-0.79 |
| FCF / Share |
-0.61 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
57,747 |
| Short Ratio |
0.04 |
| Short % of Float |
0.32% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.44 |
| Revenue |
n/a |
| Operating Income |
-8.30M |
| Net Income |
-8.19M |
| Free Cash Flow |
-6.44M |
| Net Cash |
4.95M |
| Net Cash / Share |
0.37 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-57.61% |
| ROE |
-94.73% |
| ROIC |
-3,463.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
5.00
Current: 1.32
High
5.00
Target: 5.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -8.24 | -6.99 | -1.00 | -0.41 |
| Net Income | -8.59 | -11.63 | -1.14 | -0.42 |
| Shares Outstanding | 9.85 | 4.76 | 3.26 | 3.26 |
| Earnings Per Share | -0.87 | -2.44 | -0.35 | -0.13 |
| Operating Cash Flow | -6.34 | -2.50 | -0.49 | -0.27 |
| Free Cash Flow | -6.34 | -2.50 | -0.49 | -0.27 |
| Cash & Equivalents | 6.78 | 3.87 | 0.02 | 0.12 |
| Total Debt | - | - | 0.69 | 0.23 |
| Net Cash / Debt | 6.78 | 3.87 | -0.67 | -0.11 |
| Assets | 7.68 | 4.70 | 0.03 | 0.15 |
| Liabilities | 0.54 | 0.26 | 1.03 | 0.26 |
| Book Value | 7.14 | 4.44 | -1.00 | -0.10 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Adial Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
3 |
| CEO |
William B. Stilley |
Stock Information
| Ticker Symbol |
ADIL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ADIL |
| IPO Date |
July 30, 2018 |
Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.